90642-81-2

Usage

Uses

Used in Pharmaceutical Synthesis:
2-Amino-2-phenylpropan-1-ol is used as an important intermediate in the synthesis of various pharmaceuticals, particularly those with anti-adrenergic activity. Its unique chemical structure and reactivity contribute to the development of drugs with targeted therapeutic effects.
Used in Organic Synthesis:
In the field of organic synthesis, 2-Amino-2-phenylpropan-1-ol is utilized as a nucleophile or base due to its basic secondary amine functionality. This versatility allows it to participate in a wide range of chemical reactions, facilitating the creation of diverse organic compounds for various applications.

InChI:InChI=1/C9H13NO/c1-9(10,7-11)8-5-3-2-4-6-8/h2-6,11H,7,10H2,1H3

Upstream product

• 20398-59-8 ethyl 2-amino-2-phenylpropanoate 
• 4507-40-8 2-(benzyloxycarbonylamino)-2-phenylpropanoic acid 
• 4355-46-8 α-amino-α-methylphenylacetonitrile 
• 98-86-2 acetophenone 
• 565-07-1 2-amino-2-phenylpropanoic acid 

Downstream Products

• 943780-50-5 benzyl N-(2-hydroxy-1-methyl-1-phenyl)ethylcarbamate 
• 1617545-95-5 2-(6-chloro-pyrazin-2-ylamino)-2-phenyl-propan-1-ol 
• 1617545-79-5 2-[6-(3-chloro-phenyl)-pyrazin-2-ylamino]-2-phenyl-propan-1-ol 
• 1043488-68-1 (RS)-4-methyl-4-phenyl-4,5-dihydrooxazol-2-ylamine 
• 1353226-56-8 C₉H₁₃NO₄S 
• 1335117-44-6 4-methyl-4-phenylthiazolidine-2-thione 

Relevant academic research and scientific papers

Site-Specific C(sp3)–H Aminations of Imidates and Amidines Enabled by Covalently Tethered Distonic Radical Anions

The utilization of N-centered radicals to synthesize nitrogen-containing compounds has attracted considerable attention recently, due to their powerful reactivities and the concomitant construction of C?N bonds. However, the generation and control of N-centered radicals remain particularly challenging. We report a tethering strategy using SOMO-HOMO-converted distonic radical anions for the site-specific aminations of imidates and amidines with aid of the non-covalent interaction. This reaction features a remarkably broad substrate scope and also enables the late-stage functionalization of bioactive molecules. Furthermore, the reaction mechanism is thoroughly investigated through kinetic studies, Raman spectroscopy, electron paramagnetic resonance spectroscopy, and density functional theory calculations, revealing that the aminations likely involve direct homolytic cleavage of N?H bonds and subsequently controllable 1,5 or 1,6 hydrogen atom transfer.

NOVE PHENYL/PYRIDINE SERIES SUBSTITUED BY HYDROXYETHYLAMINO FOR THE TREATMENT OF CANCER

The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6, R7 and W are as described herein, compositions including the compounds and methods of using the compounds.

NITRATED HYDROCARBONS, DERIVATIVES, AND PROCESSES FOR THEIR MANUFACTURE

Provided is a process for the formation of nitrated compounds by the nitration of hydrocarbon compounds with dilute nitric acid. Also provided are processes for preparing industrially useful downstream derivatives of the nitrated compounds, as well as novel nitrated compounds and derivatives, and methods of using the derivatives in various applications.

AMINOALCOHOL AND BIOCIDE COMPOSITIONS FOR AQUEOUS BASED SYSTEMS

Biocidal compositions and their use in aqueous media, such as metalworking fluids, the compositions comprising a biocidal agent; and a non-biocidal primary amino alcohol compound of the formula (I): wherein R1, R2, R3, R4, and R5 are as defined herein.

Versatile synthesis of free and N-benzyloxycarbonyl-protected 2,2-disubstituted taurines

An effective and versatile method was developed to synthesize N-benzyloxycarbonyl-protected and free 2,2-disubstituted taurines. Several novel 2,2-disubstituted taurines, including aliphatic/aromatic and cyclic/acyclic derivatives, were obtained, which demonstrates the generality of this method. Wiley-VCH Verlag GmbH & Co. KGaA, 2008.

NOVEL 2-AMINOOXAZOLINES AS TAAR1 LIGANDS FOR CNS DISORDERS

The invention relates to the use of compounds of Formula (I) wherein R 1 is hydrogen, deuterium, tritium, lower alkyl, lower alkoxy, lower alkyl substituted by halogen, lower alkoxy substituted by halogen, halogen, phenyl optionally substituted by halogen, or is phenyloxy, benzyl, benzyloxy, -COO-lower alkyl, -O-(CH 2 ) o -O-lower alkyl, NH-cycloalkyl, cycloalkyl or tetrahydropyran-4-yloxy, wherein the substituents for n> 1 may be the same or different; X is a bond, -CHR-, -CHRCHR'-, -OCH 2 -, -CH 2 OCHR-, -CH 2 CH 2 CH 2 -, -SCH 2 -, -S(O) 2 CH 2 -, -CH 2 SCH 2 -, -CH 2 N(R)CH 2 -, -cycloalkyl-CH 2 - or SiRR'-CH 2 -; R/R' may be independently from each other hydrogen, lower alkyl or lower alkyl substituted by halogen; R 2 is hydrogen, phenyl or lower alkyl; Y is phenyl, naphthyl, thiophenyl, pyridinyl, cycloalkyl, 1,2,3,4-tetrahydro-naphthalen-2-yl, 2,3-dihydrobenzo[1,4]dioxin-6-yl or benzo[1,3]dioxol-5-yl; n is 0, 1, 2 or 3; o is 2 or 3; or to a pharmaceutically suitable acid addition salt for the manufacture of medicaments for the treatment of diseases related to the biological function of the trace amine associated receptors, which diseases are depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders, schizophrenia, neurological diseases, Parkinson's disease, neurodegenerative disorders, Alzheimer's disease, epilepsy, migraine, substance abuse and metabolic disorders, eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders